Document Detail

A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients.
MedLine Citation:
PMID:  20554567     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Candida non-albicans species cause an increasing proportion of invasive candidiasis (IC). Prompt initiation of effective antifungal therapy has been shown to positively impact the outcomes of IC. Caspofungin is often reserved as a second-line agent after suboptimal response to initial therapy. We determined the impact of the timing of caspofungin administration on outcomes of IC. METHODS: Medical records were reviewed on all hospitalized adults who received >or=72 h of caspofungin for IC (isolation of Candida species from blood, intra-abdominal or other sterile sites). Clinical data were extracted from medical charts and recorded. Patients were classified based on delayed initiation (DI; >3 days) versus early initiation (EI; <or=3 days) of caspofungin relative to the time the culture was obtained. RESULTS: A total of 169 patients received caspofungin for IC; Candida glabrata (n = 78, 46%) was the most common cause, followed by mixed species (n = 36, 21%), Candida albicans (n = 36, 21%), Candida parapsilosis (n = 9, 6%), Candida tropicalis (n = 6, 3%), Candida krusei and other species (n = 4, 2%). Infection sites were bloodstream related (n = 119, 71%), intra-abdominal (n = 44, 26%) and other sterile sites (n = 6, 3%). DI of caspofungin was associated with a lower response rate (35/62, 56% versus 82/107, 77%; P = 0.006), longer time to achieve clinical stability (10 versus 4 days; P = 0.002) and longer length of stay after isolation of the organism (28 versus 21 days; P = 0.007), compared with EI (n = 107). CONCLUSIONS: Non-albicans Candida species accounted for the majority of IC in caspofungin-treated patients. Improved outcomes were observed for patients initiated with caspofungin within 72 h of positive culture compared with those who received delayed therapy.
Donald I Hsu; Megan Nguyen; Lee Nguyen; Anandi Law; Annie Wong-Beringer
Related Documents :
11486457 - Age as limiting factor of the efficacy of itraconazole for treatment of onychomycosis.
14742987 - Comparative safety of amphotericin b lipid complex and amphotericin b deoxycholate as a...
8601647 - Treatment of dermatophyte nail infections: an open randomized study comparing intermitt...
17526917 - Caspofungin for the treatment of less common forms of invasive candidiasis.
2053097 - The effect of different anaesthetic techniques on the incidence of thrombosis following...
21168637 - Liver transplantation in a randomized controlled trial of emergency treatment of acutel...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2010-06-16
Journal Detail:
Title:  The Journal of antimicrobial chemotherapy     Volume:  65     ISSN:  1460-2091     ISO Abbreviation:  J. Antimicrob. Chemother.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-16     Completed Date:  2010-10-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513617     Medline TA:  J Antimicrob Chemother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1765-70     Citation Subset:  IM    
Western University College of Pharmacy, 309 E. Second Street, Pomona, CA 91766, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antifungal Agents / administration & dosage*
Candida / classification,  isolation & purification
Candidiasis / drug therapy*,  microbiology
Cohort Studies
Echinocandins / administration & dosage*
Middle Aged
Retrospective Studies
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Antifungal Agents; 0/Echinocandins; 0/caspofungin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Successful treatment with tigecycline of two patients with complicated urinary tract infections caus...
Next Document:  Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic revi...